Recon: Oxford, CanSino coronavirus vaccines trigger immune response; GSK buys 10% stake in CureVac

• White House seeks to block funds for coronavirus testing and tracing in relief bill (CNBC)
• Mistrust of a Coronavirus Vaccine Could Imperil Widespread Immunity (NYTimes)
• Inside Johnson & Johnson’s nonstop hunt for a coronavirus vaccine (NYTimes)
• More than 100,000 have signed up for coronavirus vaccine testing (The Hill)
• Gene Therapy Shows Promise For Hemophilia, But Could Be Most Expensive U.S. Drug Ever (NPR)
• Congress is back to hash out coronavirus relief (Politico)
• How much will it cost? And 5 other questions Congress could push Covid-19 vaccine makers to answer (STAT)
• Janssen/MeiraGTx sight loss gene therapy hits targets (PharmaTimes)

• Studies provide glimpse at efficacy of Covid-19 vaccines from Oxford-AstraZeneca and CanSino (STAT)
• Oxford vaccine triggers immune response (BBC) (Endpoints) (The Lancet)
• CanSino COVID-19 Vaccine Shows Immune Response in Human Trial (Reuters) (Endpoints) (The Lancet)
• UK Orders 90 Million Covid-19 Vaccine Doses from Pfizer, Valneva (Bloomberg)
• Sanofi forges ahead with active ingredients spin-off-sources (Reuters) (Endpoints)
• GSK scoops up close to 10% of German vaccine producer CureVac (Financial Times) (Endpoints)
• Pre-fab vaccine facilities aim to help fill production gap (Financial Times)
• Tiny UK Company’s Stock Soars 552% as Drug Cuts Covid Risk (Bloomberg) (PMLive)
• BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech (Endpoints)
• Allergan Pulls EU Filing For Abicipar Pegol (Pink Sheet)

• What Does It Mean to Say a New Drug ‘Works’? (Wired)
• New studies clarify what drugs help, hurt for COVID-19 (NBC)
• WHO reports record number of new coronavirus cases as death toll nears 600,000 (NBC)
• Older Children Spread the Coronavirus Just as Much as Adults, Large Study Finds (NYTimes)
• Immunosuppressant drug shows promise for Covid-19 patients (Financial Times)
• Testing Backlogs May Cloud the True Spread of the Coronavirus (NYTimes)
• For COVID Tests, the Question of Who Pays Comes Down to Interpretation (KHN)
• Coronavirus vaccines: top shots (Financial Times)
• Seven Indian pharmaceutical companies race to develop vaccine for deadly coronavirus (Economic Times)
• Coronavirus (COVID-19) Update: Daily Roundup July 17, 2020 (FDA)

• Art Krieg’s Checkmate executes a snappy 1-2 biotech gambit — big crossover followed by an instant IPO (Endpoints)
• Small AI biotech BioXcel surges on positive PhIII results, setting up dementia and Alzheimer’s test (Endpoints)
• USP Convention Meets Virtually in May 2020 to Review Upcoming Priorities, with Both 200-Year Legacy and Current Pandemic in Focus (IPQ)
• Amplyx touts upbeat readout from a small PhII study for lead antifungal (Endpoints)
• Ex-Sanofi Genzyme chief David Meeker hops to a new biotech CEO post, this time focusing on quick leap to commercialization (Endpoints)
• FDA 'Consistency' Is Industry Watchword For Promoting Effective Drug Development (Pink Sheet)
• Industry Calls For US FDA Transparency On Use Of Innovative Clinical Trial Designs (Pink Sheet)
• US FDA's Postmarket Study Requirements: Industry Wants Standardization, Expert Input (Pink Sheet)
• US FDA May Reconsider RMAT Requests If Resubmitted With Sufficient Clinical Data (Pink Sheet)
• Leave a Ladder Down, Part Deux (LifeSciVC)
• Over 158 applications for generic products pending with USFDA for approval: Lupin (Economic Times)
• DCGI pulls up Glenmark for false claims, overpricing of coronavirus drug FabiFlu (Economic Times)

• Philips sees double-digit COVID-19 connected care bump amid Q2 sales dip (MedtechDive)
• FDA says Verathon recall of GlideScope Core smart cable is Class I (MassDevice)
• Orthofix wins FDA clearance for pediatric plating system (MassDevice)

• Substantial Obstacles after June Medical Services: ACOG v. FDA (Harvard Bill of Health)
• Cipla settles case with Amgen Inc involving generic cinacalcet hydrochloride tablets (Economic Times)